Emerging Data and Future Directions in UC

Video

Experts highlight emerging data and novel regimens that have the biggest potential to impact treatment and management of patients with urothelial cancer.

Recent Videos
5 experts in this video
5 experts in this video
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
Related Content
Antihistamines Added to IO Associated with Longer Survival in Urothelial Carcinoma

Antihistamines Added to IO Associated with Longer Survival in Urothelial Carcinoma

Tim Cortese
March 4th 2025
Article

Retrospective analyses found that antihistamines added to atezolizumab yielded a 46% OS rate, a 48% CSS rate, and a 23% PFS rate in patients with metastatic urothelial carcinoma.

NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Petros Grivas, MD, PhD;David Morris, MD, MS
March 4th 2025
Podcast

The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.

Durable Responses in Low-Grade, Intermediate-Risk NMIBC with UGN-102

Durable Responses in Low-Grade, Intermediate-Risk NMIBC with UGN-102

Ashling Wahner
February 15th 2025
Article

Data from the ENVISION and ATLAS trials demonstrated clinically meaningful responses with UGN-102 in the treatment of low-grade, intermediate-risk NMIBC.

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Oncology Peer Review On-The-Go: Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer

Matthew Fowler;Jun Gong, MD
March 15th 2022
Podcast

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

The safety profile of dato-DXd in the phase 1 TROPION-PanTumor01 trial is comparable with prior reports of the agent.

Dato-DXd Yields Encouraging Activity in Pretreated Advanced Bladder Cancer

Russ Conroy
February 15th 2025
Article

The safety profile of dato-DXd in the phase 1 TROPION-PanTumor01 trial is comparable with prior reports of the agent.

Avelumab Maintenance Extends Survival in Advanced Urothelial Carcinoma, Regardless of Diabetes

Avelumab Maintenance Extends Survival in Advanced Urothelial Carcinoma, Regardless of Diabetes

Jax DiEugenio
February 14th 2025
Article

Avelumab maintenance demonstrated improved survival outcomes in advanced urothelial carcinoma, including patients with diabetes, in the JAVELIN Bladder 100 study.